Compare OLP & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | ALLO |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.2M | 539.4M |
| IPO Year | 1995 | 2018 |
| Metric | OLP | ALLO |
|---|---|---|
| Price | $22.62 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $26.75 | $8.35 |
| AVG Volume (30 Days) | 52.1K | ★ 14.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | $142,416.42 |
| P/E Ratio | $19.80 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $0.86 |
| 52 Week High | $25.90 | $4.46 |
| Indicator | OLP | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 42.55 |
| Support Level | $22.11 | $1.70 |
| Resistance Level | $23.42 | $2.71 |
| Average True Range (ATR) | 0.43 | 0.32 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 18.10 | 10.54 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.